Your browser does not support JavaScript! SODIUM BICARBONATE SOLUTION [SAGENT PHARMACEUTICALS]
DailyMed Logo Header image

Daily Med

Current Medication Information

Options

RxNorm Names

SODIUM BICARBONATE solution
[Sagent Pharmaceuticals]


Category DEA Schedule Marketing Status
HUMAN PRESCRIPTION DRUG LABEL Unapproved drug for use in drug shortage
Drug Label Sections

SAGENT™

Sagent Pharmaceuticals, Inc.

1901 N. Roselle Road, Suite 700
Schaumburg, IL 60195
(847) 908-1600 Main
(847) 908-1601 Fax
www.SagentPharma.com

URGENT – Sodium Bicarbonate Injection Shortage Update

January 7, 2013

Dear Healthcare Professional,

Due to the current critical shortage of Sodium Bicarbonate Injection, USP in the United States (US) market, Sagent Pharmaceuticals, Inc. (Sagent) is coordinating with the Food and Drug Administration (FDA) to increase the availability of Sodium Bicarbonate Injection. In cooperation with the FDA, Sagent has initiated temporary importation of a non FDA approved 8.4% Sodium Bicarbonate Injection (1 mEq/mL) from Phebra Pty Ltd (Phebra), Australia into the US market.

Phebra's Sodium Bicarbonate Injection contains the same active ingredient, Sodium Bicarbonate, in the same strength and concentration, 8.4% (1 mEq/mL) as the US registered Sodium Bicarbonate Injection, USP by Hospira. However, it is important to note that Phebra's Sodium Bicarbonate Injection (1 mEq/mL), is provided only in a Single Use 10 mL vial, whereas Hospira's product is provided in 50 mL single-dose vials and syringes. Any unused portion of Phebra's Sodium Bicarbonate Injection (1 mEq/mL) should be discarded after a single use.

Please refer to the US approved package insert at http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.DrugDetails for the full prescribing information for8.4% Sodium Bicarbonate Injection (1 mEq/mL).

Phebra's Sodium Bicarbonate labeling does not include an NDC number. To order Phebra's 8.4% Sodium Bicarbonate Injection, (1 mEq/mL), 10 mL vial, please contact your Sagent Regional Business Manager or call Sagent's Customer Service at 1-866-625-1618 and reference item number 32982.

To report adverse events or medication errors among patients who have received Phebra's 8.4% Sodium Bicarbonate Injection, (1 mEq/mL), 10 mL vial, please contact Medical Affairs by phone at 1-866-625-1618. Adverse events may also be reported to FDA's MedWatch Adverse Reporting Program either online, by regular mail or fax:

  • Online: www.fda.gov/medwatch/report.htm
  • Regular Mail: use postage-paid FDA Form 3500 available at www.fda.gov/Medwatch/getforms.htm. Mail to: MedWatch, FDA, 5600 Fishers Lane, Rockville, MD 20852-9787
  • Fax: 1-800-FDA-0178

If you have any questions about the information contained in this letter or the safe and effective use of Phebra's 8.4% Sodium Bicarbonate Injection, (1 mEq/mL), 10 mL vial, please contact Sagent's Medical Affairs at 1-866-625-1618.

At this time, no other entity except Sagent Pharmaceuticals, Inc. is authorized by the FDA to import or distribute Phebra's 8.4% Sodium Bicarbonate Injection, (1 mEq/mL), 10 mL vials, in the United States. Any sales of this product from any entity other than Sagent Pharmaceuticals, Inc. or a distributor or re-seller authorized by Sagent Pharmaceuticals, Inc. could be a violation of the Federal Food, Drug and Cosmetic Act and is subject to enforcement by the FDA.

Sincerely,




Thomas J. Moutvic
Vice President, Regulatory Affairs
Sagent Pharmaceuticals, Inc.

PACKAGE LABEL – PRINCIPAL DISPLAY PANEL – Vial Label

Sodium Bicarbonate

8.4% Injection 840mg in 10mL

10 x 10mL vials

PACKAGE LABEL – PRINCIPAL DISPLAY PANEL – Vial Label
SODIUM BICARBONATE 
sodium bicarbonate solution
Product Information
Product TypeHUMAN PRESCRIPTION DRUG LABELItem Code (Source)NDC:25021-501
Route of AdministrationINTRAVENOUSDEA Schedule    
Active Ingredient/Active Moiety
Ingredient NameBasis of StrengthStrength
sodium bicarbonate (sodium cation and bicarbonate ion) sodium bicarbonate84 mg  in 1 mL
Inactive Ingredients
Ingredient NameStrength
water 
Packaging
#Item CodePackage DescriptionMarketing Start DateMarketing End Date
1NDC:25021-501-6610 in 1 CARTON
110 mL in 1 VIAL
Marketing Information
Marketing CategoryApplication Number or Monograph CitationMarketing Start DateMarketing End Date
Unapproved drug for use in drug shortage10/02/201201/31/2015
Labeler - Sagent Pharmaceuticals (796852890)

Revised: 2/2013
 
Sagent Pharmaceuticals

Visit The National Library of Medicine Copyright, Privacy, Accessibility
U.S. National Library of Medicine, 8600 Rockville Pike, Bethesda, MD 20894
National Institutes of Health, Health & Human Services